ESLAW
Estrella Immunopharma Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
-0.09
52W High
$0.24
52W Low
$0.03
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -174.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-2.89 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $9.10M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/15/2026